Navigation Links
Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance
Date:12/11/2008

in Europe for maintenance treatment of adult patients with schizophrenia who are sufficiently stabilized during acute treatment with oral Zyprexa. In the U.S., the company has submitted a complete response to the FDA's not approvable letter and is currently awaiting the FDA's final review.

-- Gamma Secretase Inhibitor - In March 2008, the company began its first pivotal trial in Alzheimer's disease for the gamma secretase inhibitor, a small molecule designed to reduce the levels of the amyloid beta peptide in the brain. The trial, called IDENTITY, is actively enrolling and is ahead of schedule. A second pivotal trial, IDENTITY 2, was started in September 2008 and is also enrolling at a better-than-expected rate. Approximately 400 subjects have now been randomized in the two studies.

-- A-beta Antibody - A monoclonal antibody, the company's A-beta antibody offers the potential for slowing down the progression of Alzheimer's disease. It is expected to enter Phase III in 2009.

-- Enzastaurin - A Phase III clinical trial is currently under way for the use of enzastaurin as a maintenance therapy for diffuse large B-cell lymphoma. Because events are occurring at a slower rate than projected, the company is considering expanding enrollment and extending the trial. The company now expects U.S. regulatory submission to occur in mid-2013.

-- Teplizumab - The company continues to collaborate with its partner, MacroGenics Inc., on teplizumab, which is currently being studied in a pivotal Phase II/III clinical trial for Type 1 diabetes.

-- Dirucotide (MBP8298) - Along with its partner, BioMS, the company is studying dirucotide for the treatment of several types of multiple sclerosis (MS). There are two Phase III clinical trials ongoing targeting secondary progressive MS, one in Europe and Canada, and the other in the U.S. There is also a Phase II clinical trial underway in Europe for rel
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
7. Lilly Announces Termination of AIR Insulin Program
8. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
9. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
10. Lilly Reports Solid First-Quarter Results
11. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Regis Technologies looks forward to being part ... (AACR) annual meeting. Regis will exhibit at this year's ... 18, in Philadelphia and running through April 22, 2015. ... oldest and largest organization focused on cancer research. It ... with survivors to promote awareness and research funding. ...
(Date:4/16/2015)... April 16, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... Exchange: PBT.U), is pleased to announce that the Company ... April 25, 2015 to be held in ... Bailey and Mr. James Mellon , a ... update on the key programs at its subsidiaries, Portage ...
(Date:4/16/2015)... SAN DIEGO , April 16, 2015 /PRNewswire/ ... and development of therapeutic antibodies, today announced ... (IL-36R) antibody program into IND-enabling studies. The ... a novel treatment for generalized pustular psoriasis ... high unmet medical need. ANB019 is wholly owned ...
(Date:4/16/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company ... new orphan drug indications, today announced that the ... a clinical trial site for the ongoing, multicenter Phase ... multiforme (GBM), the most common and deadly form of ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5
... Jan. 22 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX:,LOR; ... research and,development of pharmaceutical products and technologies for ... strengthened its management team,with the appointment of Mr. ... (CFO)., Mr. Korth has previously held senior ...
... of Record for FOSRENOL(R), SARATOGA SPRINGS, N.Y., Jan. ... company, is pleased to announce that Shire,Pharmaceuticals (LSE: SHP, ... record to lead the professional advertising and promotion for,Shire,s ... "We are excited to put our team,s experience ...
... N.J., Jan. 22 Ikaria Holdings, Inc., a ... S. Zoth has been elected as an independent ... the former Chief Financial Officer of,MedImmune, will chair ... fortunate to have an executive with Lota,s background ...
Cached Biology Technology:Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer 2Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer 3Shire Engages Palio 2Shire Engages Palio 3Lota Zoth Elected to Ikaria Board and Named Audit Committee Chair 2
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ... Iris Recognition Market 2015-2019" report to their offering. ... market to grow at a CAGR of 23.5 percent ... the present scenario and the growth prospects of the ... calculate the market size, the report considers the revenue ...
(Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
(Date:3/23/2015)... -- In the 2014 fiscal year, irs.gov recorded over $100 ... accounts for a fraction of the estimated losses for ... $11 billion globally. The polygraph has traditionally been used ... Investor Mark Saint Juste along with former ... partnered to administer the test in a new way: ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... ALLENTOWN, N.J. , April 3, 2013 HireLifeScience.com, the ... host its 4 th annual career fair at The ... on October 1, 2013.  Doors will open for ... at 4 p.m.  The event is being sponsored by Actavis, ...
... technology vital for tapping much-needed energy or one that,s environmentally ... explore at the Technology and Society Forum session on fracking ... Campus Center Ballroom. The NJIT Technology and Society Forum ... for hydraulic fracturing, injects fluid underground at high pressure to ...
... Laboratory (NPL), the UK,s National Measurement Institute, could help ... injuries such as muscle strains and ligament damage. ... in physiotherapy to accelerate healing of tissue injuries. Ideally, ... treatment site, but it is well-known that this does ...
Cached Biology News:Registration Now Open for Elite Life Science Career Fair 2Fracking: Challenges and opportunities 2Measuring ultrasound for better treatment of muscle injuries 2
... ANTI-RNase is a protein ribonuclease inhibitor that noncovalently ... No inhibition is seen with RNase 1, T1, ... distinct from human placental ribonuclease inhibitor in that ... and does not release active RNase in the ...
...
UGT1A7 (E-15)...
... nucleofection of optimized cell lines in combination ... nucleofection parameters. Nucleofector Kits are only functional ... cell lines can be transfected with this ... given in brackets in percent (Efficiency [%] ...
Biology Products: